Table 2.

Multivariate relative risks of total, low/high stage, and low/high grade prostate cancer for current vs. nonuse of statins, among 5069 men in the MrOS cohort

Cases (total N)Age and site adjusted OR95% CIPCases (total N)Multivariate ORa95% CIP
Total356 (5069)1.240.98–1.570.07298 (4120)1.070.82–1.400.63
Gleason <7155 (4868)1.130.80–1.610.49135 (3957)1.070.73–1.590.72
Gleason ≥ 7195 (4908)1.290.95–1.760.10157 (3979)1.040.73–1.500.82
Low stage (T1/T2)252 (4965)1.160.88–1.540.29209 (4031)1.000.73–1.370.99
High stage (T3/T4)100 (4813)1.400.92–2.130.1286 (3908)1.290.80–2.070.30
  • an = 4,120 (298 cases) due to missing data for covariates; model additionally adjusted for race, BMI, marital status, family history of prostate cancer, number of comorbidities, physical activity, and smoking history.